Cargando…

Clinical characteristics and management of immune checkpoint inhibitor‐related pneumonitis: A single‐institution retrospective study

INTRODUCTION: The increasing application of immune checkpoint inhibitors (ICIs) will cause more checkpoint inhibitor‐related pneumonitis (CIP), which is a common cause of ICI‐related death. The clinical management of CIP needs further optimization. METHODS: Patients who were managed at Peking Union...

Descripción completa

Detalles Bibliográficos
Autores principales:	Wang, Hanping, Zhao, Yanwei, Zhang, Xiaotong, Si, Xiaoyan, Song, Peng, Xiao, Yi, Yang, Xu, Song, Lan, Shi, Juhong, Zhao, Haitao, Zhang, Li
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	John Wiley and Sons Inc. 2020
Materias:	Clinical Cancer Research
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7826478/ https://www.ncbi.nlm.nih.gov/pubmed/33211395 http://dx.doi.org/10.1002/cam4.3600

Ejemplares similares

Clinical diagnosis and treatment of immune checkpoint inhibitor‐associated pneumonitis
por: Wang, Hanping, et al.
Publicado: (2019)

Analysis of cytokines in bronchoalveolar lavage fluid in patients with checkpoint inhibitor pneumonitis and pulmonary infection: A case–control study
por: Si, Xiaoyan, et al.
Publicado: (2023)

Radiation Versus Immune Checkpoint Inhibitor Associated Pneumonitis: Distinct Radiologic Morphologies
por: Chen, Xuguang, et al.
Publicado: (2021)

Risk factors and immunomodulators use in steroid-refractory checkpoint inhibitor pneumonitis
por: Li, Yanlin, et al.
Publicado: (2023)

Immune-related pneumonitis associated with immune checkpoint inhibitors in lung cancer: a network meta-analysis
por: Chen, Xinru, et al.
Publicado: (2020)

Deciphering pathogenic cellular module at single-cell resolution in checkpoint inhibitor-related pneumonitis
por: Cui, Pengfei, et al.
Publicado: (2023)

Incidence and Risk Factors for Pneumonitis Associated With Checkpoint Inhibitors in Advanced Non-Small Cell Lung Cancer: A Single Center Experience
por: Altan, Mehmet, et al.
Publicado: (2023)

Real-world incidence and impact of pneumonitis in patients with lung cancer treated with immune checkpoint inhibitors: a multi-institutional cohort study
por: Tiu, Bruce C, et al.
Publicado: (2022)

Clinical recommendations on diagnosis and treatment of immune checkpoint inhibitor‐induced renal immune‐related adverse events
por: Zheng, Ke, et al.
Publicado: (2020)

Chronic immune checkpoint inhibitor pneumonitis
por: Naidoo, Jarushka, et al.
Publicado: (2020)

Current progress of immune checkpoint inhibitors in the treatment of advanced hepatocellular carcinoma
por: Yin, Xiaoqiang, et al.
Publicado: (2022)

Comprehensive Analysis of the Immune Microenvironment in Checkpoint Inhibitor Pneumonitis
por: Lin, Xinqing, et al.
Publicado: (2022)

Single-cell transcriptomics identifies pathogenic T-helper 17.1 cells and pro-inflammatory monocytes in immune checkpoint inhibitor-related pneumonitis
por: Franken, Amelie, et al.
Publicado: (2022)

Comprehensive Pneumonitis Profile of Thoracic Radiotherapy Followed by Immune Checkpoint Inhibitor and Risk Factors for Radiation Recall Pneumonitis in Lung Cancer
por: Lu, Xiaotong, et al.
Publicado: (2022)

Real-World Data of Different Immune Checkpoint Inhibitors for Non-Small Cell Lung Cancer in China
por: Miao, Kang, et al.
Publicado: (2022)

Correction: Chronic immune checkpoint inhibitor pneumonitis
Publicado: (2020)

Chinese expert consensus on the multidisciplinary management of pneumonitis associated with immune checkpoint inhibitor
por: Wang, Wenxian, et al.
Publicado: (2022)

Radiation pneumonitis in patients with non-small-cell lung cancer receiving chemoradiotherapy and an immune checkpoint inhibitor: a retrospective study
por: Jang, Jeong Yun, et al.
Publicado: (2021)

Peripheral Blood Lymphocyte Subsets Predict the Efficacy of Immune Checkpoint Inhibitors in Non–Small Cell Lung Cancer
por: Miao, Kang, et al.
Publicado: (2022)

Clinical characteristics and therapeutic effects of checkpoint inhibitor-related pneumonitis in patients with non-small cell lung cancer
por: Pang, Li, et al.
Publicado: (2023)

Corrigendum: Peripheral blood lymphocyte subsets predict the efficacy of immune checkpoint inhibitors in non– small cell lung cancer
por: Miao, Kang, et al.
Publicado: (2022)

Retrospect and Prospect for Lung Cancer in China: Clinical Advances of Immune Checkpoint Inhibitors
por: Lu, Shun, et al.
Publicado: (2019)

Proposed clinical phases for the improvement of personalized treatment of checkpoint inhibitor–related pneumonitis
por: Zhou, Chengzhi, et al.
Publicado: (2022)

Pretreatment Lung Function and Checkpoint Inhibitor Pneumonitis in NSCLC
por: Reuss, Joshua E., et al.
Publicado: (2021)

Immune checkpoint inhibitors as first-line therapy for non-small cell lung cancer: A systematic evaluation and meta-analysis
por: Lu, Yu, et al.
Publicado: (2023)

Recommendations and exploration of diagnosis and treatment of critical and refractory immune checkpoint inhibitor‐associated adverse events
por: Song, Peng, et al.
Publicado: (2020)

Clinical characteristics and prognostic model for extensive‐stage small cell lung cancer: A retrospective study over an 8‐year period
por: Ni, Jun, et al.
Publicado: (2021)

Clinical manifestation and management of immune checkpoint inhibitor‐associated cardiotoxicity
por: Guo, Xiaoxiao, et al.
Publicado: (2019)

Relationship between the efficacy of immunotherapy and characteristics of specific tumor mutation genes in non‐small cell lung cancer patients
por: Song, Peng, et al.
Publicado: (2020)

Association of Clinical and Radiological Features with Disease Severity of Symptomatic Immune Checkpoint Inhibitor-Related Pneumonitis
por: Zhang, Qian, et al.
Publicado: (2023)

Recommendation for the diagnosis and management of immune checkpoint inhibitor related infections
por: Lu, Minya, et al.
Publicado: (2020)

The development of a tumor‐associated autoantibodies panel to predict clinical outcomes for immune checkpoint inhibitor‐based treatment in patients with advanced non‐small‐cell lung cancer
por: Zhao, Jing, et al.
Publicado: (2023)

Treatment- and immune-related adverse events of immune checkpoint inhibitors in advanced lung cancer
por: Shao, Jun, et al.
Publicado: (2020)

Treatment of steroid‐resistant checkpoint inhibitor pneumonitis with pirfenidone: A case report
por: Miao, Kang, et al.
Publicado: (2021)

Success and failure of additional immune modulators in steroid-refractory/resistant pneumonitis related to immune checkpoint blockade
por: Beattie, Jason, et al.
Publicado: (2021)

Management of immune checkpoint inhibitor‐related rheumatic adverse events
por: Zhou, Jiaxin, et al.
Publicado: (2019)

Imaging Mass Cytometry Analysis of immune Checkpoint Inhibitor-Related Pneumonitis: A Case Report
por: Cheng, Yuan, et al.
Publicado: (2022)

Rate and risk factors of recurrent immune checkpoint inhibitor-related pneumonitis in patients with lung cancer
por: Tao, Haitao, et al.
Publicado: (2022)

Characterization of immunomodulatory factors and cells in bronchoalveolar lavage fluid for immune checkpoint inhibitor-related pneumonitis
por: Wang, Peng-Mei, et al.
Publicado: (2023)

Pneumonitis Induced by Immune Checkpoint Inhibitors: From Clinical Data to Translational Investigation
por: Zhu, Shicong, et al.
Publicado: (2020)

Cannot write session to /tmp/vufind_sessions/sess_gepm4e7am2nmeii6b9gmg1p33k